Chromosome 7p11.2 (EGFR) variation influences glioma risk.

While gliomas are the most common primary brain tumors, their etiology is largely unknown. To identify novel risk loci for glioma, we conducted genome-wide association (GWA) analysis of two case-control series from France and Germany (2269 cases and 2500 controls). Pooling these data with previously reported UK and US GWA studies provided data on 4147 glioma cases and 7435 controls genotyped for 424 460 common tagging single-nucleotide polymorphisms. Using these data, we demonstrate two statistically independent associations between glioma and rs11979158 and rs2252586, at 7p11.2 which encompasses the EGFR gene (population-corrected statistics, P(c) = 7.72 × 10(-8) and 2.09 × 10(-8), respectively). Both associations were independent of tumor subtype, and were independent of EGFR amplification, p16INK4a deletion and IDH1 mutation status in tumors; compatible with driver effects of the variants on glioma development. These findings show that variation in 7p11.2 is a determinant of inherited glioma risk.

[1]  W. Foulkes,et al.  A Practical Guide to Human Cancer Genetics , 2013 .

[2]  K. Hoang-Xuan,et al.  Genetic Risk Profiles Identify Different Molecular Etiologies for Glioma , 2010, Clinical Cancer Research.

[3]  Susan M. Chang,et al.  Inherited variation in immune genes and pathways and glioblastoma risk , 2010, Carcinogenesis.

[4]  G. Reifenberger,et al.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. Kleihues,et al.  IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.

[6]  Forest M White,et al.  Oncogenic EGFR Signaling Networks in Glioma , 2009, Science Signaling.

[7]  K. Hoang-Xuan,et al.  Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Melissa Bondy,et al.  Genome-wide association study identifies five susceptibility loci for glioma , 2009, Nature Genetics.

[9]  Alexander R. Pico,et al.  Variants in the CDKN2B and RTEL1 regions are associated with high grade glioma susceptibility , 2009, Nature Genetics.

[10]  A. Kaye,et al.  The EGFRvIII variant in glioblastoma multiforme , 2009, Journal of Clinical Neuroscience.

[11]  K. Hemminki,et al.  Familial risks in nervous-system tumours: a histology-specific analysis from Sweden and Norway. , 2009, The Lancet. Oncology.

[12]  K. Hoang-Xuan,et al.  Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma , 2009, Neuropathology and applied neurobiology.

[13]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[14]  Tarik Tihan,et al.  Brain tumor epidemiology: Consensus from the Brain Tumor Epidemiology Consortium , 2008, Cancer.

[15]  H. Blom,et al.  The methylenetetrahydrofolate reductase (MTHFR) variant c.677C>T (A222V) influences overall survival of patients with glioblastoma multiforme. , 2008, Neuro-oncology.

[16]  Emmanuel Barillot,et al.  BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas , 2007, International journal of cancer.

[17]  Naohito Yamaguchi,et al.  The INTERPHONE study: design, epidemiological methods, and description of the study population , 2007, European Journal of Epidemiology.

[18]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.

[19]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.

[20]  P. Kleihues,et al.  Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.

[21]  C. Woods,et al.  A Practical Guide to Human Cancer Genetics , 1993 .

[22]  S. Gabriel,et al.  Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain , 2006, PLoS medicine.

[23]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[24]  Michael Krawczak,et al.  PopGen: Population-Based Recruitment of Patients and Controls for the Analysis of Complex Genotype-Phenotype Relationships , 2006, Public Health Genomics.

[25]  D. Clayton,et al.  Population structure, differential bias and genomic control in a large-scale, case-control association study , 2005, Nature Genetics.

[26]  R Holle,et al.  KORA - A Research Platform for Population Based Health Research , 2005, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).

[27]  C. Gieger,et al.  KORA-gen - Resource for Population Genetics, Controls and a Broad Spectrum of Disease Phenotypes , 2005, Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)).

[28]  Alain Favier,et al.  The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. , 2004, Archives of internal medicine.

[29]  D. Grönemeyer,et al.  Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. , 2002, American heart journal.